Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Combination Therapy Publisher



Keshavarzfathi M1, 2, 3 ; Rezaei N3, 4, 5
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran
  3. 3. Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  5. 5. Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tehran, Iran

Source: Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives Published:2019


Abstract

The efficacy of cancer vaccines as a monotherapy may be undervalued because of immunosuppression and immune regulatory functions. Combining vaccines with other therapeutics can overcome these barriers and enhance the efficacy of cancer vaccines. Cancer vaccines have been combined with other therapeutics such as chemotherapy, radiation therapy, and small molecule inhibitors, as well as immunotherapy such as cytokines, immune checkpoint inhibitors, and tumor targeted monoclonal antibodies. These combinations have been evaluated in many preclinical and clinical studies. Here, we will review these combination therapies and their potential for improving the efficacy of vaccines. © 2019 Nima Rezaei and Mahsa Keshavarz-Fathi Published by Elsevier Ltd. All rights reserved.
1. Combination Therapy: Cancer Vaccines and Other Therapeutics, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
2. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
3. Obstacles in the Development of Therapeutic Cancer Vaccines, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
4. Tumor Immunology, Clinical Immunology (2022)
Experts (# of related papers)
Other Related Docs
10. Hurdles in Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
11. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2020)
13. Monoclonal Antibodies for Cancer Immunotherapy, Cancer Immunology: Bench to Bedside Immunotherapy of Cancers# Second Edition (2020)
14. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
16. Chimeric Antigen Receptor T-Cell Therapy for Melanoma, Expert Review of Clinical Immunology (2021)
17. Peptide and Protein Vaccines for Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
18. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2019)
20. Immunotherapeutic Approaches in Cancer, Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives (2018)
21. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
25. Cancer Immunotherapy Confers a Global Benefit, Cancer Immunology: Cancer Immunotherapy for Organ-Specific Tumors (2015)